(29.06.2020)

Rep. Lloyd Doggett, D-Texas, called the price „outrageous.“

„Without a taxpayer investment of $99 million, this drug would have been abandoned. It would be on the scrap heap of failures,“ he tells NPR. „So it‘s the taxpayer who‘s really taking the risk here and ought to get the reward of the angel investors that taxpayers are.“

Public Citizen, a nonprofit consumer advocacy group, echoed his remarks with a similar sentiment.